Overview

Alternate-Day Buprenorphine Administration. Phase I - 3

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborator:
University of Vermont
Treatments:
Buprenorphine
Criteria
Please contact site for information.